Maternal fructose drives placental uric acid production leading to adverse fetal outcomes

Zeenat A. Asghar1, Alysha Thompson2, Maggie Chi3, Andrew Cusumano1, Suzanne Scheaffer1, Noor Al-Hammadi2, Jessica L. Saben1 & Kelle H. Moley1

Maternal metabolic diseases increase offspring risk for low birth weight and cardiometabolic diseases in adulthood. Excess fructose consumption may confer metabolic risks for both women and their offspring. However, the direct consequences of fructose intake per se are unknown. We assessed the impact of a maternal high-fructose diet on the fetal-placental unit in mice in the absence of metabolic syndrome and determined the association between maternal serum fructose and placental uric acid levels in humans. In mice, maternal fructose consumption led to placental inefficiency, fetal growth restriction, elevated fetal serum glucose and triglyceride levels. In the placenta, fructose induced de novo uric acid synthesis by activating the activities of the enzymes AMP deaminase and xanthine oxidase. Moreover, the placentas had increased lipids and altered expression of genes that control oxidative stress. Treatment of mothers with the xanthine oxidase inhibitor allopurinol reduced placental uric acid levels, prevented placental inefficiency, and improved fetal weights and serum triglycerides. Finally, in 18 women delivering at term, maternal serum fructose levels significantly correlated with placental uric acid levels. These findings suggest that in mice, excess maternal fructose consumption impairs placental function via a xanthine oxidase/uric acid-dependent mechanism, and similar effects may occur in humans.

Consumption of sugar and high-fructose corn syrup is on the rise and has been implicated in development of metabolic syndrome, which includes obesity, dyslipidemia, hypertension, and diabetes14,2. Moreover, in both rats and humans, excess fructose consumption leads to hyperuricemia and insulin resistance3,4, which are strongly associated with metabolic syndrome and type 2 diabetes.

Fructose consumption may contribute to metabolic disease because of the way it is metabolized. Unlike glucose, whose metabolism is tightly regulated to produce ATP, the bulk of ingested fructose is extracted at first pass in the liver, where it is rapidly converted to fructose-1-phosphate by phosphofructokinase5. Conversion of fructose to fructose-1-phosphate leads to cellular depletion of ATP and activation of AMP deaminase (AMPD); AMPD converts AMP to xanthine, which is then converted to uric acid by xanthine oxidase1. This has two consequences. First, whereas extracellular uric acid can act as a potent antioxidant and is beneficial, excess intracellular uric acid can lead to oxidative stress and cellular dysfunction1,4-7. Second, excess uric acid can lead to increased de novo lipogenesis, thereby causing lipotoxicity and promoting oxidative stress and inflammation7,8. This effect may explain why excess fructose intake can promote accumulation of intrahepatic triglyceride in both healthy and type 2 diabetic subjects and lead to the development or worsening of non-alcoholic fatty liver disease9-11.

Maternal metabolic diseases are associated with increased obstetric complications such as preeclampsia, gestational diabetes, poor placentation, and intrauterine growth restriction. However, in the absence of metabolic diseases, consumption of sucrose and sugar-sweetened beverages can also increase the risk for developing preeclampsia12,13. It is well established that nutritional and other environmental exposures during fetal development can permanently affect the composition, homeostatic systems, and functions of multiple organs and systems14,15. Thus, pregnancy complications predispose the offspring to poor metabolic health in adulthood16. Accordingly, many human and rodent studies have shown that changes to maternal diet can lead to an adverse intrauterine environment that impairs fetal development and increases offspring risk of future diseases (reviewed in)17.

1Department of Obstetrics & Gynecology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. 2Department of Biostatistics, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. Correspondence and requests for materials should be addressed to J.L.S. (email: sabenj@wudosis.wustl.edu) or K.H.M. (email: moleyk@wudosis.wustl.edu)
adaptations to pregnancy were perturbed in the HFrD-fed mice. Other metabolic features such as insulin levels, did not differ in pregnant and non-pregnant HFrD-fed mice. This observation suggests that some physiological cohort of women delivering at term by cesarean.

To assess human relevance of our mouse data, we examined the association between maternal serum fructose and placental uric acid in a small placental defects and investigate the mechanism by which this occurs. Additionally, to assess human relevance of the end of the six-week feeding paradigm (Supplementary Fig. S1). Thus, HFrD feeding in mice led to only a few metabolic derangements with either some21–23 or no metabolic consequence in the offspring24.

We recently showed that in C57BL6 mice, exposure to a high-fructose diet conferred few of the phenotypes associated with metabolic syndrome25 but did lead to smaller litter sizes, which was, at least in part, due to a defect in decidualization. This model thus allows us to investigate the effects of a high-fructose diet on reproductive outcomes without confounding by the full metabolic syndrome. Here, we demonstrate that HFrD-exposed mice have placental defects and investigate the mechanism by which this occurs. Additionally, to assess human relevance of our mouse data, we examined the association between maternal serum fructose and placental uric acid in a small cohort of women delivering at term by cesarean.

Results
Metabolic effects of high-fructose diet on mice during pregnancy. We previously demonstrated that consumption of a high-fructose diet (HFrD) led to impaired glucose tolerance but not weight gain, insulin resistance, or triglyceridemia in pseudo-pregnant C57BL6 female mice25. Here, we asked what effect HFrD consumption had on virgin females. As anticipated, HFrD-fed mice consumed food at a similar rate as control chow-fed mice and exhibited impaired glucose tolerance but not weight gain, insulin resistance, or triglyceridemia at the end of the six-week feeding paradigm (Supplementary Fig. S1). Thus, HFrD feeding in mice led to only a few features of metabolic syndrome with no gross dietary deficiencies, particularly protein. This enabled us to examine the direct effects of elevated fructose on pregnancy.

We next mated the mice to males maintained on a control chow diet and measured maternal and fetal serum values of metabolites on day post-coital (dpc) 18.5 (Table 1). Serum glucose and fructose levels were significantly elevated in HFrD-fed mothers and in their fetuses. Serum triglyceride levels were decreased in the HFrD-fed mothers but increased in their fetuses. This finding led us to investigate the mothers’ physiological adaptations to pregnancy. In control chow-fed mice, serum triglyceride (0.54 ± 0.03 mM vs. 0.32 ± 0.02 mM) and cholesterol (1.39 ± 0.1 mM vs. 0.79 ± 0.07 mM) levels were higher in pregnant than non-pregnant mice as expected as these are normal physiological responses during pregnancy26. In HFrD-fed mice, levels of serum triglycerides were also higher in pregnant than in non-pregnant mice (0.38 ± 0.03 mM vs. 0.30 ± 0.01 mM), but the difference was significantly smaller than in controls. Additionally, cholesterol levels (1.01 ± 0.03 mM vs. 0.92 ± 0.07 mM) did not differ in pregnant and non-pregnant HFrD-fed mice. This observation suggests that some metabolic adaptations to pregnancy were perturbed in the HFrD-fed mice. Other metabolic features such as insulin levels, insulin sensitivity (QUICKI), uric acid levels (Table 1) and maternal blood pressure (Supplementary Table S1) were equivalent between HFrD- and control chow-fed pregnant mice. However, HFrD- but not control chow-fed pregnant mice had hepatic steatosis at dpc 18.5 (Supplementary Fig. S2).

Maternal high-fructose diet leads to fetal growth restriction and placental inefficiency. We found that fetuses of mothers that consumed HFrD had smaller weights than fetuses of control chow-fed mothers (Fig. 1a), but crown-rump lengths were similar between the two groups (data not shown). Placental weights were significantly larger on average in HFrD-fed mice than in chow-fed control mice (Fig. 1b). This resulted in a significant decrease in the fetal-to-placental weight ratio in HFrD mice (Fig. 1c), suggesting that HFrD consumption led to placental inefficiency. Moreover, placentas of HFrD-fed mice had a larger diameter than those of control chow-fed mice (Fig. 1d) and showed zone-specific changes in area (Fig. 1e). The maternally derived decidua was larger in HFrD mice, whereas the labyrinth zone, which is primarily responsible for maternal-fetal exchange, was smaller (Fig. 1f), consistent with the presence of placental inefficiency.

Fructose drives uric acid production in the placenta. Given that fructose metabolism drives uric acid production in the liver (Fig. 2a3), we wondered whether a similar effect occurred in the placentas of HFrD-fed
mice. Indeed, placental uric acid was significantly higher in placentas of HFrD-fed mice than in those of control chow-fed mice (Fig. 2b). Fructokinase was expressed in the mouse placenta, but it did not increase significantly in HFrD-fed mice (Fig. 2c). Consistent with the fructose-uric acid pathway (Fig. 2a), placentas of HFrD-fed mice had lower levels of ATP (Fig. 2d) and higher AMPD activity (Fig. 2e) than those of control chow-fed mice. AMPD converts AMP to inosine monophosphate, which leads to the production of xanthine via xanthine oxidase (Fig. 2a). We found that xanthine oxidase activity (Fig. 2f) and expression (Fig. 2g) were higher in placentas from HFrD-fed mothers than in placentas from control chow-fed mothers. In rodents, the hepatic enzyme uricase further converts uric acid to a harmless by-product, allantoin27. We found that uricase was expressed in the liver but not in the placenta (Supplementary Fig. S3). Together with our observation that HFrD-fed mothers did not have elevated serum uric acid (Table 1), these data indicate that excess fructose consumption induced de novo placental production of uric acid through increased AMPD and xanthine oxidase activity. In addition, due to the lack of uricase expression in the placenta, uric acid accumulation occurs.

**Figure 1. Maternal high-fructose diet decreases placental efficiency.** (a) Fetal weights, (b) placental weights, (c) fetal to placental weight ratios, (d) placental diameter, (e) representative H&E staining of placental sections at dpc 18.5, and (f) quantification of placenta zone areas. D, decidua; J, Junctional zone; L, Labyrinth; n = 7–8 mothers in each group. Data are presented as mean and standard error of the mean. *P < 0.05, **P < 0.01 by Student's t-test.

Maternal high-fructose diet causes lipid accumulation and oxidative stress in the placenta. Fructose can induce lipid accumulation in hepatocytes in a uric acid-dependent manner8, and we found that placentas of HFrD-fed mice had significantly more triglycerides, particularly in the decidua, than those of control-chow-fed mice (Fig. 3a). Accumulation of excess triglycerides in cells leads to oxidative stress29 and oxidative stress is often observed in placentas from growth-restricted fetuses29. Therefore, we hypothesized that uric acid-induced oxidative stress contributes to the smaller fetal size in HFrD-exposed offspring. To explore this possibility, we examined levels of protein modification by 4-Hydroxynonenal (4-HNE), a diffusible product of lipid peroxidation that has been implicated as a key mediator of oxidative stress-induced cell death30. We found that placentas of HFrD-fed mice had a significant increase in levels of 4-HNE-modified proteins (Fig. 3b), suggesting that excess fructose induces a pro-oxidant environment within the placenta. To further characterize the oxidative state of fructose-exposed placentas, we measured levels of the antioxidant enzymes superoxide dismutase 1 and 2 (SOD1 and SOD2), which convert superoxide radicals to hydrogen peroxide and oxygen, and glutathione peroxidase and catalase, which detoxify excess hydrogen peroxide (Fig. 3c). Levels of both SOD2 (Fig. 3d) and SOD1 (data not shown) were higher in placentas of HFrD-fed mice than in those of control chow-fed mice, but only the SOD2 difference was statistically significant. Levels of both glutathione peroxidase (Fig. 3e) and catalase (Fig. 3f) were significantly lower in placentas of HFrD-fed mice than in controls. This deficiency in glutathione peroxidase and catalase coupled with increased SOD expression suggests that optimal protection from oxidative stress may be reduced and inefficient in HFrD-exposed placentas.

**Figure 2. Maternal high-fructose diet induces altered placental physiology.** (a) Fructose-uric acid pathways. Uricase further converts uric acid to allantoin in the liver. (b) Uric acid is accumulated in the placenta. (c) Placentas of HFrD-fed mice had lower levels of ATP than those of control chow-fed mice. (d) AMPD converts AMP to inosine monophosphate, which leads to the production of xanthine via xanthine oxidase. (e) Placentas of HFrD-fed mice had higher AMPD activity than those of control chow-fed mice. (f) Xanthine oxidase activity was higher in placentas of HFrD-fed mothers than in placentas of control chow-fed mothers. (g) Xanthine oxidase expression was higher in placentas of HFrD-fed mothers than in placentas of control chow-fed mothers.
Allopurinol rescues adverse placental and fetal outcomes. To determine whether xanthine oxidase-induced uric acid was responsible for the adverse maternal-fetal outcomes of HFrD exposure, we treated the mice with the xanthine oxidase inhibitor allopurinol. Allopurinol can be supplied in the drinking water and can readily cross the placenta31. Not surprisingly, allopurinol treatment beginning three weeks before and throughout pregnancy did not reverse the pre-pregnancy glucose intolerance observed in HFrD-fed mice (Fig. 4a,b). Allopurinol treatment of HFrD-fed mothers improved fetal weights, but not significantly ($P = 0.06$, Fig. 4c). However, placental weight (Fig. 4d), placental diameter (Fig. 4f), fetal-to-placental weight ratio (Fig. 4e), and placental uric acid levels (Fig. 4g) were fully normalized in the allopurinol-treated HFrD-fed dams. Finally, the fetuses of allopurinol-treated HFrD-fed mice had serum triglyceride levels that were comparable to those of the controls (Fig. 4h). Together, these data suggest that excess uric acid in the placenta contributes to placental inefficiency and that maternal allopurinol treatment could ameliorate both placental effects and fetal hypertriglyceridemia resulting from maternal HFrD exposure.

Placental uric acid is correlated with maternal serum fructose in human pregnancy. To explore the clinical relevance of our findings, we examined the relationship between maternal serum fructose and uric acid in term placentas from a small cohort of women ($n = 18$) undergoing non-laboring cesarean deliveries. Clinical characteristics of the women and babies are presented in Supplementary Table S2.

We measured uric acid levels in three different placental layers and found a significant correlation between maternal serum fructose and level of uric acid in the placental villous tree but not in the basal plate or sub chorion (Fig. 5). After accounting for a number of potential confounders (Supplementary Table S3), the association between maternal serum fructose and placental villous tree uric acid level remained stable and significant, suggesting that maternal serum fructose level is an independent predictor of placental villous tree uric acid levels. We then asked how well maternal serum fructose could predict placental villous tree uric acid levels as an outcome. Because of our small sample size, a multivariate analysis was not feasible; therefore, we ran a univariate linear regression analysis to examine the effect of maternal serum fructose in predicting the placental villous tree uric acid levels as an outcome. We used the log transformation of the outcome to meet the normality assumption of the linear regression model (Supplementary Table S4). The estimating strength of maternal serum fructose as a predictor was moderate with a $R^2$ value of 0.44 and a 1.002 (ng/mg protein) increase in placental villous tree uric acid levels was found for every 1 mM increase in maternal serum fructose levels ($P = 0.003$). Because maternal
serum fructose, but not serum uric acid, correlated with placental villous tree uric acid levels (Supplementary Table S4), our data suggest that increased circulating fructose in pregnant women drives placental uric acid production.

Discussion
Increased fructose consumption has been linked to metabolic syndrome, but the effects of fructose consumption during pregnancy on maternal and offspring health are less well characterized. In this study, we used a murine model to test the effects of elevated fructose consumption on fetal-placental development. Maternal HFrD exposure led to increased uric acid in the placenta but not in the maternal serum, indicating that the placenta produced excess uric acid. Additionally, maternal HFrD exposure led to a pro-oxidative placental milieu, fetal growth restriction, and fetal hypertriglyceridemia. Many of these effects were normalized by treating the mothers with allopurinol, indicating that placental xanthine oxidase and uric acid are responsible for the fructose-induced placental and fetal impairments. Furthermore, our observation in a small cohort of women that maternal serum fructose correlated with levels of uric acid in placentas suggests that similar effects occur in humans.

Our findings in mice differ from those in rats on a high-fructose diet, which exhibit many features of metabolic syndrome such as hyperglycemia, hyperinsulinemia/insulin resistance, hypertension, hyperuricemia, and...
Figure 4. Allopurinol prevents adverse fetal-placental phenotypes. Mice were untreated (white bars) or treated with allopurinol (+ AP, black bars). (a) Glucose tolerance test after 3 weeks of allopurinol treatment; n = 5 in allopurinol group, n = 12 in untreated group, \#P < 0.001 control vs. HFrD, \#P < 0.0001 control vs. HFrD + AP, $P < 0.01 control vs. HFrD + AP. (b) Quantification of area under the curve (AUC) from data in (a). (c–h) Measurements on dpc 18.5 of (c) fetal weight, (d) placental weight, (e) fetal to placental ratio, (f) placental diameter, and (g) intra-placental uric acid levels in pooled placental samples; n = 8 mothers in allopurinol group, n = 12 in untreated group. (h) Fetal serum triglyceride levels; pooled serum from n = 4–6 mothers. Data are presented as mean and standard error of the mean. Identical letters indicate no statistical difference between groups, and different letters indicate significance (at least P < 0.05) as determined by 2-way ANOVA and Tukey post-hoc analysis.
Studies examining effects of the fructose-uric acid pathway in preeclamptic placentas are currently ongoing. A study of 32,933 nulliparous women in New Zealand suggests that maternal fructose could play a role in placental uric acid production, which could contribute to endothelial dysfunction and inefficient placentation. Additionally, xanthine oxidase activity is elevated in placentas from preeclamptic patients and xanthine oxidase can promote placental oxidative stress and apoptosis. In this study, treatment with allopurinol led to significantly lower placental uric acid levels and rescued the fructose-induced placental inefficiency. Therefore, treatment with allopurinol may reduce overall levels of oxidative stress in a way that is not specific to increases in uric acid. Moreover, allopurinol is commonly used to treat hyperuricemia in humans, and one consequence of treatment is improved endothelial function. Whether placental endothelial defects occur as a result of HFrD exposure in mice remains to be determined.

Several epidemiological studies have shown that IUGR or low birth weight increase the risk of developing metabolic syndrome, type 2 diabetes, and cardiovascular disease in adulthood. In this study, we did not follow the HFrD-exposed fetuses to adulthood. However, fetuses from HFrD-fed mice had elevated circulating glucose and lipids and were growth restricted, suggesting they were at increased risk of future cardio-metabolic diseases.

We acknowledge that uric acid homeostasis in rodents is unlike that of humans. However, humans have higher serum urate levels compared to rodents due to the genetic silencing of the hepatic enzyme uricase, which metabolizes uric acid into allantoin. Thus, the negative effect of excess fructose in humans is likely to lead to an exacerbation of the mouse phenotype. In our human studies, we found that maternal serum fructose level was an independent predictor of placental villous tree uric acid and that the maternal serum uric acid level did not confound this relationship. This favors the notion that, as in mice, fructose may drive de novo production of uric acid.
acid in the human placenta. Although few data exist on placental fructose transport, we previously showed that the hexose transporters GLUT846 and GLUT947 can transport fructose and are expressed in human placentas48,49. This correlation between maternal serum fructose and placental uric acid should be confirmed in a larger cohort suitable for multivariate analyses, and the underlying mechanism should be further investigated. Finally, our study is limited by the fact that term placentas were used to assess the relationship between serum fructose and placental uric acid. Since many of the placental disorders associated with oxidative stress (IUGR and preeclampsia) result from much earlier changes in placental development, the uric acid content at term is not necessarily reflective of the original insult. However, first and second trimester tissues are not readily available making it extremely difficult to perform such studies.

In conclusion, our work indicates a novel mechanism by which increased fructose consumption can negatively affect maternal-fetal outcomes. The impact of fructose consumption on human health has become increasingly important since the introduction of high fructose corn into the US food supply just before 1970. Now, high fructose corn syrup constitutes over 50% of the sweeteners used and Americans consume on average 26.8 pounds of HFCS per capita per year (http://www.ers.usda.gov/data-products/sugar-and-sweeteners-yearbook-tables.aspx). The work presented herein gives premise to the necessity of understanding the potentially negative effects of high fructose diets in humans, in particular during pregnancy.

**Methods**

**Animal diet, breeding, and treatment.** All procedures were performed in accordance with the approved guidelines by the Animal Studies Committee at Washington University School of Medicine. Six-week-old C57BL6/J female mice (Jackson Laboratory, Bar Harbor, ME) were fed a high-fructose diet (HFrD; Harlan Teklad, Madison, WI) or standard rodent chow ad libitum for six weeks. HFrD was similar to the control chow except that the complex carbohydrates (corn starch, maltodextrin, and 3% sucrose) were replaced with 60% fructose. The percent kilocalories obtained from carbohydrates (66.8% HFrD vs. 62.1% chow) and fat (12.9% HFrD vs. 13.2% chow) were similar between the two diets. Food intake was measured two or three times per week and averaged weekly and was similar between the two groups (Supplementary Fig. S1). Body weights were measured weekly throughout the duration of the study. After six weeks of feeding, both HFrD- and chow-fed mice were mated overnight to chow-fed C57BL6/J male mice. The male was removed once mating was confirmed via appearance of a vaginal plug the next morning (day post-coital [dpc] 0.5). Mice were maintained on their respective diets throughout pregnancy until they were sacrificed on dpc 18.5. For allopurinol treatment, mice were provided with drinking water containing 150 mg/L allopurinol three weeks before and during pregnancy. Mice were maintained on a 12-h light/dark cycle.

**Mouse glucose and insulin tolerance tests.** Mice were fasted for six hours before glucose tolerance tests or four hours before insulin tolerance tests. Blood glucose was measured before mice were injected intraperitoneally with 2 mg of glucose per gram of body weight for glucose tolerance tests or 0.5 units of insulin per gram of body weight for insulin tolerance tests. The one-touch Bayer Contour T5 glucometer (Mishiwaka, IN) was used for all glucose measurements. The quantitative insulin-sensitivity check index (QUICKI) was used to determine insulin sensitivity in pregnant dams and fetuses where $\text{QUICKI} = 1/(\log(\text{fasting insulin}) + \log(\text{fasting glucose}))$ as described previously50.

**Mouse placental and fetal tissue collection.** On dpc 18.5, blood pressure of the mothers was measured by using Columbus Instruments’ Non-Invasive Blood Pressure Monitor system (NIBP S/N 110707-1). Mothers were fasted for four hours before blood collection via the submandibular/facial vein. Mice were then euthanized in accordance with animal studies committee regulations. Individual fetal-placental units were dissected from the uterine horns, and fetal membranes were discarded before weighing and measuring. Placental weights, placental diameter, fetal weights, and crown-rump lengths were measured. Fetal sex was determined visually under a dissecting microscope by gonadal identification. Both male and female placentas were analyzed in all experiments and combined for data analysis, as no sex-based differences were observed. Placental tissue was rinsed in ice-cold PBS before snap freezing in liquid nitrogen or processing for procedures listed below. All samples were stored at −80°C until use. Fetal trunk blood was collected and pooled from each litter. For all measurements, values from −80°C until use. Fetal trunk blood was collected and pooled from each litter. For all measurements, values from

**Human tissue collection.** All experimental protocols were performed in accordance with the guidelines and regulations at Washington University School of Medicine. Human tissue samples were collected by the Women and Infants’ Health Specimen Consortium and the collection protocol was approved by the Institutional Review Board at Washington University (201409097). A written informed consent was obtained from all subjects prior to tissue collection at term. Women participating in this study were chosen to represent a range of race, body mass index, and metabolic disease such that their defined characteristics followed a normal distribution pattern. All participants delivered full-term infants whose weights were normal for gestational age. Sera, placentas, and umbilical cord blood (mixed arterial and venous) were collected from pregnant women delivering at term at Barnes-Jewish Hospital. Included in this study were mothers who had non-laboring cesarean deliveries. Clinical characteristics were obtained from medical records. Three 5 mm² samples were collected from each of three distinct placental zones – basal plate, villosus tree, and sub-chorion – to ensure adequate coverage of the entire placenta. Non-fasting maternal serum was averaged from participants at the time of delivery.

**Serum measurements.** Serum levels of fructose (Intra-assay coefficient of variance, %CV = 3.4) and uric acid (%CV = 2.3) in humans were measured with the Fructose Assay Kit (#F8000-11, US Biologicals) and the Infinity Uric Acid Reagent (#TR24321, Thermo Scientific), respectively, according to manufacturers’ instructions. Serum triglyceride (%CV = 8.9%), cholesterol (%CV = 5.8), non-esterified free fatty acids (%CV = 1.9), and
insulin (%CV = 4.6) were measured in mice fasted for four hours by using the infinity triglyceride & cholesterol reagent kit (Fisher Diagnostics), the NEFA-HR (2) assay kit (Wako Diagnostics), and the rat/mouse insulin ELISA kit (Crystal Chem, IL), respectively, according to the manufacturers' instructions. The Washington University Mass Spectrometry Core Facility measured mouse serum uric acid levels as previously described52. Serum glucose (%CV = 2.1) and fructose (%CV = 1.3 levels) in mice were determined as previously described46-52.

Quantitative real-time RT-PCR and Immunoblotting. Mouse placentas were individually snap-frozen and used for RNA extraction and subsequent PCR quantification or lysed for immunoblotting. RNA was isolated by using TRIzol reagent (Invitrogen). The Quantitect Qiagen reverse transcriptase kit (Qiagen, Valencia, CA) was used to synthesize cDNA. Quantitative PCR (7500/7500 fast real-time PCR system, software version 2.0.3, Applied Biosystems) was performed using the SYBR Green master mix (reagent from Applied Biosystems, Carlsbad, CA). The PCR reaction was carried out for 40 cycles of 95 °C for 20 s, 95 °C for 3 s, and 60 °C for 30 s. Quantification of gene expression was determined using the ΔΔCt approach normalizing to beta-actin. Primers used were: fructokinase - 5′TAG GAC ACG AAC CTG CCA GA3′ and 5′ CAC CTG TTC CGA TGC ATT CC3′, beta-actin – 5′ACC TTC TAC AAT GAG CTG CG3′ and 5′CTG GAT GCC TAG TGA CAT GG3′. Primer efficiency was determined by generating a standard curve from a cDNA pool of all our sample groups. The amplification efficiency was 96.8% for fructokinase and 94% for beta-actin primers. Primers were specific for the genes as the dissociation curves had single peaks and no shoulders and had melting temperatures above 80 °C indicating no primer-dimer formations. Beta-actin expression was independent of treatment.

For all immunoblot analysis, 20 μg of total protein lysate was loaded per lane. Immunoblots were incubated overnight in TBST/5% milk containing antibodies specific to the following proteins: Uricase (1:500; Santa Cruz Biotechnology, TX), Superoxide 2 (SOD2) (1:1000; Santa Cruz Biotechnology, TX), Glutathione peroxidase, catalase, beta-actin, 4HNE (all 1:1000; Abcam, MA), and cyclophilin B (1:5000; Abcam). Blots were washed and probed with goat secondary antibody conjugated to horseradish peroxidase (1:5000). Chemiluminescence was detected by using the Super Signal West Pico kit (Thermo Scientific).

Histology and immunohistochemistry. After animal sacrifice, cross-sections of each placenta were cut and fixed overnight in 10% neutral buffered formalin (Fisher Scientific) or cryopreserved in optimal cutting temperature compound (Tissue-Tek). Formalin-fixed placentas were processed into paraffin blocks and cut into 5 μm sections for further histological analyses. The placental sections were stained with Hematoxylin and Eosin, and areas of placental zones were measured with ImageJ analysis software (version 1.47). The Vectastain Elite ABC kit (Vector labs, MI) was used for immunohistochemical detection. Primary antibodies recognized xanthine oxidase (1:100; Abcam, MA). Oil-red-o analysis of cryopreserved placentas was performed as previously described46 and quantified by ImageJ analysis software (version 1.47). An average of four or five placentas per mother and at least five mothers in each group were used for all the above analyses.

Placental metabolite quantification. To measure mouse and human placental uric acid concentration, placental tissue was homogenized in PBS and centrifuged at 4 °C. The internal standard (1 ng/μl of 1-methyl uric acid) and 70% methanol were immediately added to the supernatant, which was then dried under a stream of nitrogen and re-dissolved in 500 μl of water. Analysis was performed as previously described52 at the Washington University Mass Spectrometry Core Facility. ATP levels in mouse placentas were measured as previously described52. To determine XO and AMPD activity in mouse placentas, each fresh placenta was homogenized in ice-cold 100 mM Tris HCl, 1 mM EDTA, pH 7.5, and centrifuged at 9,300xg for 10 minutes. The supernatant was used to quantify XO activity according to the manufacturer's instructions (Cayman Chemicals, MI). Before measuring AMPD activity in placental samples, two reagent mixtures were prepared and pre-treated. First, the 2X AMPD reagent (60 mM Imidazole base, 25% glycerol, 0.1% fraction V & protease-free BSA, 2 mM DTT, 2 mM ATP, 10 mM 5′-AMP, and 200 mM KCl) was pre-treated with 25 mM acetic anhydride for 10 minutes at room temperature. Second, 2X NH4 reagent (100 mM Trizma base, 0.04% fraction V & protease-free BSA, 200 μM ADP, 2 mM α-ketoglutarate) was pre-treated with 12.5 mM acetic anhydride at room temperature for 10 minutes. After pre-treatment, 400μM NADH and 160 μg/ml GDH in glycerol was added to the mix. To measure AMPD activity, the placental supernatant was diluted 1:400 in 20 mM Imidazole HCl, pH 7.0, and 0.05% fraction V & protease-free BSA. A 20μl sample was added to 20μl of pre-treated 2X AMPD reagent and incubated at 37 °C for 60 minutes. The reaction was stopped by adding 10μl of 0.15 N HCl and incubating at 60 °C for 20 minutes. Next, 50 μl of pre-treated 2X NH4 reagent was added, and the mixture was incubated at room temperature for 25 minutes. The reaction was terminated by adding 10 μl of 0.6 N HCl and incubating for 10 minutes at room temperature. A 10μl aliquot was added to 1 ml of 6 N NaOH and 10 mM Imidazole base, mixed immediately, and incubated at 60 °C for 20 minutes for strong base fluorescence enhancement. Fluorescence was detected with an A-1 FOCI fluorometer (Valhalla, NY) at 340 nm with internal standards generated from (NH4)2SO4. All of the above reagents were purchased from Sigma-Aldrich (St. Louis, MO).

Statistics. Data are expressed as mean ± SEM. GraphPad PRISM version 6.0 (La Jolla, CA) was used to perform either Student’s t-tests assuming two-tailed distribution and unequal variances for comparison between two groups or two-way ANOVA analyses for multiple comparisons. Correlations and univariate linear regression analyses were performed by the Institute of Clinical and Translational Sciences Biostatistics division at Washington University in St. Louis using SAS 9.3. For the univariate linear regression analysis, the log transformation of placental villous tree uric acid levels was used because the data were not normally distributed. For all data, P < 0.05 was considered statistically significant.
References

1. Johnson, R. J. et al. Sugar, uric acid, and the etiology of diabetes and obesity. *Diabetes* 62, 3307–3315, doi: 10.2337/db12-1814 (2013).

2. Tappy, L. & Le, K. A. Metabolic effects of fructose and the worldwide increase in obesity. *Physiological reviews* 90, 23–46, doi: 10.1152/physrev.00019.2009 (2010).

3. Nakagawa, T. et al. A causal role for uric acid in fructose-induced metabolic syndrome. *American journal of physiology. Renal physiology* 290, F625–631, doi: 10.1152/ajprenal.00140.2005 (2006).

4. de Oliveira, E. P. & Burini, R. C. High plasma uric acid concentration: causes and consequences. *Diabetology & metabolic syndrome* 4, 12, doi: 10.1186/1758-5996-4-12 (2012).

5. Johnson, R. J. et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? *Endocrine reviews* 30, 96–116, doi: 10.1210/er.2008-0033 (2009).

6. Havel, P. J. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. *Nutrition reviews* 63, 133–157 (2005).

7. Sautin, Y. Y., Nakagawa, T., Zarhikov, S. & Johnson, R. J. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. *American journal of physiology. Cell physiology* 293, C584–596, doi: 10.1152/ajpcell.00600.2006 (2007).

8. Roberts, J. M. et al. Uracil induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. *The Journal of biological chemistry* 287, 40732–40744, doi: 10.1074/jbc.M112.399899 (2012).

9. Schwarz, J. M. et al. Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat. *The Journal of clinical endocrinology and metabolism* 100, 2434–2442, doi: 10.1210/jc.2014-3678 (2015).

10. Ouyang, X. et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. *Journal of hepatology* 48, 993–999, doi: 10.1016/j.jhep.2008.02.011 (2008).

11. Abdelmalek, M. F. et al. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. *Hepatology* 56, 952–960, doi: 10.1002/hep.25741 (2012).

12. Borgen, I. et al. Maternal sugar consumption and risk of preeclampsia in nulliparous Norwegian women. *European journal of clinical nutrition* 66, 920–925, doi: 10.1038/ejcn.2012.61 (2012).

13. Clausen, T. et al. High intake of energy, sucrose, and polyunsaturated fatty acids is associated with increased risk of preeclampsia. *American journal of obstetrics and gynecology* 185, 451–458, doi: 10.1016/j.amoab.2001.116687 (2001).

14. Plata Miel, M. et al. Critical periods of increased fetal vulnerability to a maternal high fat diet. *Reproductive biology and endocrinology: RB&E* 12, 80, doi: 10.1186/1477-7827-12-80 (2014).

15. Lewis, R. M., Cleal, J. K. & Hanson, M. A. Review: Placenta, evolution and lifelong health. *Endocrine reviews* 33, 587–604, doi: 10.1210/pd.2011-4003 (2011).

16. Liu, W. et al. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. *Nutrients* 5, 123, doi: 10.3390/nu5020123 (2013).

17. Schwarzenberg, S. J. Uric acid and the etiology of diabetes and obesity. *Endocrine reviews* 33, 4995–5019, doi: 10.1210/en.2015-1618 (2015).

18. Clancy, D. J., May, E. J., Zhou, J., Neely, T. N., Kark, K. & Fischler, D. G. Uric acid and non-alcoholic fatty liver disease: a mechanistic study. *Atherosclerosis* 243, 90–95, doi: 10.1016/j.atherosclerosis.2015.02.021 (2015).

19. Matsui, K., Koyama, Y., Takahashi, K., Matsuoka, Y. & Osawa, E. A. Uric acid and insulin resistance: mechanisms and therapeutic implications. *Endocrinology* 152, 1378–1387, doi: 10.1210/en.2010-1093 (2011).

20. Zou, M. et al. Fructose consumption during pregnancy and lactation induces fatty liver and glucose intolerance in rats. *Nutrition research* 32, 588–598, doi: 10.1016/j.nutres.2012.06.012 (2012).

21. Mukai, T., Ozaki, H., Serita, Y. & Sato, S. Maternal fructose intake during pregnancy modulates hepatic and hypothalamic AMP-activated protein kinase signalling in a sex-specific manner in offspring. *Clinical and experimental pharmacology & physiology* 41, 331–337, doi: 10.1111/1440-1681.12225 (2014).

22. Lineker, C. et al. High fructose consumption in pregnancy alters the perinatal environment without increasing metabolic disease in the offspring. *Reproduction, fertility, and development*, 10.1071/RF15119 (2015).

23. Saben, J. L. et al. Excess maternal fructose consumption increases fetal loss and impairs endometrial decidualization in mice. *Endocrinology* 156, 1615–1618 (2015).

24. Barret, A. et al. Maternal serum cholesterol levels are elevated from the 1st trimester of pregnancy: a cross-sectional study. *American journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology* 32, 747–752, doi: 10.3109/01443615.2012.714017 (2012).

25. Alvarez-Lario, B. & Macaron-Vicente, J. I. Is there anything good in uric acid? *QJM: monthly journal of the Association of Physicians* 104, 1013–1024, doi: 10.1093/qjmed/hcl159 (2011).

26. Aon, M. A., Pericot, N. & Fantus, C. S. Pharmacologically and mechanistic considerations for lipid excess. *Frontiers in physiology* 5, 282, doi: 10.3389/fphys.2014.00282 (2014).

27. Scifres, C. M. & Nelson, D. M. Intrauterine growth restriction, human placental development and trophoblast cell death. *The Journal of physiology* 587, 4345–4358, doi: 10.1113/jphysiol.2009.173232 (2009).

28. Liu, W. et al. 4-hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. *Journal of cell science* 113 (Pt 4), 635–641 (2000).

29. Kane, A. D. et al. Maternal-to-fetal allopurinol transfer and xanthine oxide suppression in the late gestation pregnant rat. *Physiological reports* 1, e00156, doi: 10.1002/phr2.156 (2013).

30. Rawana, S. et al. Low dose fructose ingestion during gestation and lactation affects carbohydrate metabolism in rat dams and their offspring. *The Journal of nutrition* 123, 2158–2165 (1993).

31. Jen, K. L., Rochon, C., Zhong, S. B. & Whitcomb, I. Fructose and sucrose feeding during pregnancy and lactation in rats changes maternal and pup fuel metabolism. *The Journal of nutrition* 121, 1999–2005 (1991).

32. Fabbrini, E. & Magkos, F. Hepatic Steatosis as a Marker of Metabolic Dysfunction. *Nutrients* 7, 4995–5019, doi: 10.3390/nu7064995 (2015).

33. Flagstrom, H. et al. Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. *Liver international: official journal of the International Association for the Study of the Liver*, 10.1111/liv.12902 (2015).

34. Rando, O. J. & Simmons, R. A. I’m eating for two: parental dietary effects on offspring metabolism. *Cell* 161, 93–105, doi: 10.1016/j.cell.2015.02.021 (2015).

35. Bellomo, G. Serum uric acid and pre-eclampsia: an update. *Expert review of cardiovascular therapy* 10, 701–705, doi: 10.1586/erc.12.51 (2012).

36. Roberts, J. M. et al. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. *Hypertension* 46, 1263–1269, doi: 10.1161/1HYP.0000188703.27002.14 (2005).
39. Bainbridge, S. A. & Roberts, J. M. Uric acid as a pathogenic factor in preeclampsia. Placenta 29 Suppl A, S67–72, doi: 10.1016/j.placenta.2007.11.001 (2008).
40. Schneider, D. et al. Oxidative stress as common trait of endothelial dysfunction in chorionic arteries from fetuses with IUGR and LGA. Placenta 36, 552–558, doi: 10.1016/j.placenta.2015.02.003 (2015).
41. Bainbridge, S. A. et al. Uric acid attenuates trophoblast invasion and integration into endothelial cell monolayers. American journal of physiology. Cell physiology 297, C440–450, doi: 10.1152/ajpcell.00593.2008 (2009).
42. Mary, A., Hubel, C. A., Fisher, S. J., Roberts, J. M. & Zhou, Y. Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia. The American journal of pathology 156, 321–331, doi: 10.1016/S0002-9440(10)64733-5 (2000).
43. Murata, M. et al. Oxidative stress produced by xanthine oxidase induces apoptosis in human extravillous trophoblast cells. The Journal of reproduction and development 59, 7–13 (2013).
44. Poston, L. & Rajmakers, M. T. Trophoblast oxidative stress, antioxidants and pregnancy outcome—a review. Placenta 25 Suppl A, S72–78, doi: 10.1016/j.placenta.2004.01.003 (2004).
45. Hales, C. N. & Barker, D. J. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 35, 595–601 (1992).
46. Debosch, B. J., Chen, Z., Saben, J. L., Finck, B. N. & Moley, K. H. Glucose transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis. The Journal of biological chemistry 289, 10989–10998, doi: 10.1074/jbc.M113.527002 (2014).
47. Manolescu, A. R., Augustin, R., Moley, K. & Cheeseman, C. A highly conserved hydrophobic motif in the exofacial vestibule of fructose transporting SLC2A proteins acts as a critical determinant of their substrate selectivity. Molecular membrane biology 24, 455–463, doi: 10.1080/09687680701298143 (2007).
48. Doege, H., Schurmann, A., Bahrain, G., Brauers, A. & Jooost, H. G. GLUT8, a novel member of the sugar transport facilitator family with glucose transport activity. The Journal of biological chemistry 275, 16275–16280 (2000).
49. Bibee, K. P., Illsley, N. P. & Moley, K. H. Asymmetric syncytial expression of GLUT9 splice variants in human term placenta and alterations in diabetic pregnancies. Reproductive sciences 18, 20–27, doi: 10.1177/1933719110380276 (2011).
50. Katz, A. et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. The Journal of clinical endocrinology and metabolism 85, 2402–2410, doi: 10.1210/jcem.85.7.6661 (2000).
51. DeBosch, B. J., Kluth, O., Fujiwara, H., Schurmann, A. & Moley, K. Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nature communications 5, 4642, doi: 10.1038/ncomms4642 (2014).
52. Omurtag, K. et al. Modeling the effect of cigarette smoke on hexose utilization in spermatocytes. Reproductive sciences 22, 94–101, doi: 10.1177/1933719114533727 (2015).
53. Griengl, K. K. & FitzGerald, G. A. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108, 1912–1916, doi: 10.1161/01.CIR.0000093660.86242.BB (2003).

Acknowledgements
The authors thank Deborah Frank, PhD, Obstetrics and Gynecology, Washington University in St. Louis, for critical reading and editing of this manuscript. This work was supported by NIH grants HD083895 and HD065435 (KHM), a grant from the American Diabetes Association (KHM), a grant from the CTSA at Washington University (UL1 TR000448) (KHM, JLS), and the Thrasher Research Foundation (JLS).

Author Contributions
Z.A. designed and performed experiments, analyzed data, and wrote the manuscript. A.T. and M.C. performed experiments and analyzed data. S.S. and A.C. performed experiments. N.A.-H. performed statistical analyses. J.L.S. designed and performed experiments and analyzed data. S.S. and A.C. performed experiments. N.A.-H. performed statistical analyses. J.L.S. designed and performed experiments and reviewed/edited the manuscript. K.H.M. and J.S. are the guarantors of this work and had full access to all the data in the study.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Asghar, Z. A. et al. Maternal fructose drives placental uric acid production leading to adverse fetal outcomes. Sci. Rep. 6, 25091; doi: 10.1038/srep25091 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/